CRYO-CELL International, Inc. (OTCMKTS:CCEL) Director Brian L. Sheehy bought 2,100 shares of the firm’s stock in a transaction that occurred on Thursday, January 10th. The stock was purchased at an average cost of $7.00 per share, with a total value of $14,700.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
OTCMKTS:CCEL opened at $7.25 on Monday. CRYO-CELL International, Inc. has a 1-year low of $6.03 and a 1-year high of $9.98. The firm has a market capitalization of $54.17 million, a P/E ratio of 25.00 and a beta of 0.10.
CRYO-CELL International (OTCMKTS:CCEL) last released its quarterly earnings data on Monday, October 15th. The company reported $0.03 EPS for the quarter. CRYO-CELL International had a negative net margin of 3.93% and a negative return on equity of 16.83%. The firm had revenue of $7.87 million during the quarter.
Cryo-Cell International, Inc engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases.
See Also: Why is insider trading harmful?
Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.